A Phase 3 Study of RMC-6236 Versus Docetaxel in People With Advanced Non-Small Cell Lung Cancer

Full Title

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Purpose

Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.

RMC-6236 targets the proteins made by a RAS gene mutation and prevent the RAS protein from sending growth signals. By blocking these signals, RMC-6236 may help slow or stop the growth of your cancer cells.

If you take part in this study, you will be randomly assigned to get either RMC-6236 or docetaxel. RMC-6236 is taken orally (by mouth) and docetaxel is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have NSCLC that has spread and has a KRAS, NRAS, or HRAS mutation.
• Have NSCLC that keeps growing after treatment with platinum-based therapy and immunotherapy.
• Have not previously received docetaxel.
• Have recovered from the serious side effects of previous therapies before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.